Takeda Abbott Pharmaceuticals Sues Atrix

Law360, New York (November 14, 2003, 12:00 AM EST) -- Takeda Abbott Pharmaceuticals Products, Takeda Chemical Industries and Wako Pure Chemical Industries sued Atrix Laboratories and its licensee, Sanofi-Synthelabo, alleging that Atrix's Eligard delivery system infringes on a patent for a biodegradable high molecular polymer excipient held by Takeda Chemical Industries.

The Eligard products use Atrix's proprietary Atrigel sustained-release drug delivery technology, Atrix said. The liquid Eligard products are injected subcutaneously with a small gauge needle forming a solid implant in the body that slowly releases leuprolide as the implant is bioabsorbed.

Atrix chief executive David...
To view the full article, register now.